Simultaneous determination of ceftaroline, daptomycin, linezolid and rifampicin concentrations in human plasma by on-line solid phase extraction coupled to high-performance liquid chromatography–tandem mass spectrometry

Grégoire, Matthieu; Leroy, Anne-Gaëlle; Bouquié, Regis; Malandain, D.; Dailly, Éric; Boutoille, David; Renaud, Christian; Jolliet, Pascale; Caillon, Jocelyne; Deslandes, Guillaume

doi:10.1016/j.jpba.2015.10.008

Cited by 26 publications

(13 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the complex nature of serum, a procedure for removing potential interferents and proteins in sample pretreatment is often required before LC-MS/MS analysis. Protein precipitation (PPT), liquid-liquid extraction (LLE) and solid-phase extraction (SPE) are the most common methods applied to the preparation of the biological samples ( Gregoire et al, 2016 ; Hedaya et al, 2017 ; Paal et al, 2018 ; Ferrari et al, 2019 ). Compared with PPT for sample pretreatment, SPE is relatively time consuming and expensive, and LLE is relatively complicated.…”

Section: Resultsmentioning

confidence: 99%

A Novel UPLC-MS/MS Assay for the Measurement of Linezolid and its Metabolite PNU-142300 in Human Serum and its Application to Patients With Renal Insufficiency

Wang

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

The contribution of the metabolites of linezolid to the associated myelosuppression is unknown in patients who are renal impairment. In this research, the purpose of our experiment was to explore and develop a quick and robust ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) assay for the determination of linezolid and its metabolite PNU-142300 in human serum simultaneously. The analytes were prepared using a simple and convenient approach with acetonitrile for protein crash, and then separated from the matrix on a Waters Acquity Ultra performance liquid chromatography (UPLC) BEH C18 (2.1 mm × 50 mm, 1.7 μm) column in a program of gradient elution, where the mobile phase was consisted of water with 0.1% formic acid and acetonitrile, and was placed at 0.40 ml/min flow rate. Multiple reaction monitoring (MRM) was employed and conducted for UPLC-MS/MS detection with ion transitions at m/z 338.01 → 296.03 for linezolid, m/z 369.96 → 327.98 for PNU-142300 and m/z 370.98 → 342.99 for tedizolid (Internal standard, IS), respectively. This method had good linearity respectively in the calibration range of 0.01–20 μg/ml for linezolid, and 0.05–100 μg/ml for PNU-142300. In the intra- and inter-day, the precision of linezolid and PNU-142300 was below 14.2%, and the accuracy in this method was determined to be from −9.7 to 12.8%. In addition, recovery and matrix effect of the analytes were all found to be acceptable, and the analytes during the assay and storage in serum samples were observed to be stable. The novel optimized UPLC-MS/MS assay was also successfully employed to determine the concentration levels of linezolid and PNU-142300 in human serum. The results showed that linezolid-associated myelosuppression occurs more frequently in patients with renal insufficiency, and the metabolite-to-parent concentration ratio of PNU-142300 is predicted to reduce this toxicity of myelosuppression.

show abstract

Section: Resultsmentioning

confidence: 99%

A Novel UPLC-MS/MS Assay for the Measurement of Linezolid and its Metabolite PNU-142300 in Human Serum and its Application to Patients With Renal Insufficiency

Wang

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…This approach has allowed the setting-up of numerous multiplex assays for the quantification of drugs from the same therapeutic class in a single chromatographic run. This multiplex approach has been applied notably for the simultaneous analysis of antiretroviral agents (in plasma and cells) [40][41][42][43][44], anti-HCV drugs [45], targeted anticancer agents [46], antimalarials [47], antifungals [48], new generation antiepileptics [49], (Figure 2), antibiotics such as several beta-lactams (carbapenems, penicillins, cephalosporins) altogether [50][51][52][53] or combined with other antibiotics classes including linezolid, ciprofloxacin, daptomycin and rifampicin [54][55][56][57][58]. Overall, the main advantages of this approach are: i) a unique sample extraction procedure and short analytical run; ii) time saving through the establishment of simultaneous calibration curves; iii) easy application to blood samples from patients receiving either single-drugs or combination regimens.…”

Section: How To Interpret a Tdm Measurement?mentioning

confidence: 99%

The emerging role of multiplex tandem mass spectrometry analysis for therapeutic drug monitoring and personalized medicine

Décosterd

Widmer

André

et al. 2016

TrAC Trends in Analytical Chemistry

View full text Add to dashboard Cite

Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) constitutes now a key instrumental component of medical laboratory centres and has greatly facilitated the development of a considerable number of drugs assays for Therapeutic Drug Monitoring (TDM). The concept of TDM implies the measurement of concentrations of certain drugs in patients' blood, followed by dosage individualization based on patients' circulating exposure, targeting a pre-defined concentration range. This approach aims at increasing the likelihood of achieving therapeutic efficacy, while reducing the risk of toxicity. TDM can contribute to the rational individualization of critical drug treatments, notably antivirals, antibiotics, antiepileptics, psychotropic drugs and targeted anticancer agents, in the context of growing efforts towards personalized medicine. This article aims at reviewing the basic concepts, the role and the perspectives of evolution of TDM. It presents selected examples of clinical applications and gives some insights on how TDM is definitely benefiting from the tremendous development of LC-MS/MS techniques.

show abstract

“…Many in-house published methods are available to quantify several beta-lactams or linezolid. Most of the recent assays to quantify a panel of antibiotics are based on a liquid chromatography coupled with tandem mass spectrometry [19][20][21][22][23][24][25][26] that require instruments that are not readily available in many laboratories. At the best of our knowledge, there is no available method on ultra-performance liquid chromatography (UHPLC) system coupled to a photodiode array detector (PDA) to simultaneously monitor the main beta-lactams subject to TDM (MEM, piperacilline [PIP], ceftazidime [CZA] and ceftriaxone [CFT]) [27] and LZD, which could be used in combined therapy with them.…”

Section: Introductionmentioning

confidence: 99%

Simultaneous determination of 8 beta-lactams and linezolid by an ultra-performance liquid chromatography method with UV detection and cross-validation with a commercial immunoassay for the quantification of linezolid

Fage¹,

Deprez²,

Fontaine³

et al. 2021

Talanta

View full text Add to dashboard Cite

Linezolid and beta-lactams are anti-infective drugs frequently used in intensive care unit patients. Critical illness could induce alterations of pharmacokinetic parameters due to changes in the distribution, the metabolism and the elimination process. Therapeutic drug monitoring (TDM) is therefore recommended to prevent mainly under-dosing of beta-lactams or hematological and neurological toxicities of linezolid. In Multi-or Extensively-Drugs Resistant-Tuberculosis Bacteria, the regimen could include linezolid with meropenem and amoxicillin/clavulanate justifying the development of a method allowing their simultaneous quantification.The aim of this work was to develop an in-house ultra-performance liquid chromatography method with UV detection (UHPLC-PDA) allowing the simultaneous determination of 8 beta-lactams (amoxicillin, aztreonam, cefepime, ceftazidime, ceftriaxone, cefuroxime, meropenem and piperacillin) and linezolid and to crossvalidate the linezolid quantification with a new commercial immunoassay (ARK kit) tested on a Cobas analyzer. The main advantages of the immunoassay are a 24/24 h random access assay which is fully automated and results provided within 2 h.The interference due to potential co-administrated drugs was evaluated on both methods. The preanalytical factors (type of matrix, stability) for linezolid were also investigated. The influence of hemolysis, icteria or lipemia on the spectroscopic detection of the immunoassay was assessed. The analytical performances were evaluated using the accuracy profiles approach with acceptance limits fixed at ±30%. Seventy patient samples were measured using both methods.No cross-reaction with the tested anti-infective drugs as well as no influence of hemolysis, lipemia, icteria were observed. The linezolid concentration could be measured on heparinized plasma or serum without a significant difference and remained stable for at least 72h at 4 • C.The UHPLC-PDA method performed well in the analytical range investigated (0.25-50 mg/L for meropenem, 0.75-50 mg/L for linezolid and 1-200 mg/L for other beta-lactams) with an intermediate precision and a relative bias below 7.6 and 7.7%, respectively. The analytical range of the immunoassay was narrower, from 0.85 to 18.5 mg/L. The precision and relative bias were lower than 8.1% and 4.2%, respectively. Results obtained on clinical samples showed an acceptable difference between methods with a mean bias of -1.8% [95% confidence interval: -5.2% -1.6%].To conclude, both methods showed acceptable performance to perform TDM of linezolid considering the therapeutic through target of 2-8 mg/L. The choice of the method should be made according to the degree of emergency of the response required and the field of application justifying or not the simultaneous quantification of beta-lactams and linezolid.

show abstract

Simultaneous determination of ceftaroline, daptomycin, linezolid and rifampicin concentrations in human plasma by on-line solid phase extraction coupled to high-performance liquid chromatography–tandem mass spectrometry

Cited by 26 publications

References 17 publications

A Novel UPLC-MS/MS Assay for the Measurement of Linezolid and its Metabolite PNU-142300 in Human Serum and its Application to Patients With Renal Insufficiency

A Novel UPLC-MS/MS Assay for the Measurement of Linezolid and its Metabolite PNU-142300 in Human Serum and its Application to Patients With Renal Insufficiency

The emerging role of multiplex tandem mass spectrometry analysis for therapeutic drug monitoring and personalized medicine

Simultaneous determination of 8 beta-lactams and linezolid by an ultra-performance liquid chromatography method with UV detection and cross-validation with a commercial immunoassay for the quantification of linezolid

Contact Info

Product

Resources

About